MedTrace Logo

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

NCT02033317 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-05-12

Study results available
· View outcomes & findings →

Summary

This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis.

Conditions

  • Hyperkalemia

Interventions

DRUG

patiromer

15 grams/day (5 grams 3 times daily) administered orally

Sponsors & Collaborators

  • Relypsa, Inc.

    lead INDUSTRY

Principal Investigators

  • VP Clinical Development · Relypsa, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02033317 on ClinicalTrials.gov